Hyderabad Breakthrough: Indigenous Dialysis Tech Could Cut Costs by 70%, Extending Lifesaving Care to 20,000 Patients

April 23, 2026

HYDERABAD — In a landmark development for nephrology in South Asia, scientists at the Indian Institute of Chemical Technology (IICT), a premier laboratory under the Council of Scientific and Industrial Research (CSIR), have unveiled two indigenous technologies designed to disrupt the high cost of kidney care. By developing home-grown alternatives to expensive imported components, researchers have demonstrated a pathway to slash the cost of haemodialysis by up to 70%.

The innovations—comprising an ultra-thin hollow-fibre haemodialyser filter and an advanced water-purification system—have already reached an estimated 20,000 patients through successful pilot projects in Kamareddy and Marredpally. This breakthrough arrives at a critical juncture as India grapples with a rising burden of Chronic Kidney Disease (CKD), offering hope for more affordable, scalable care in rural and semi-urban regions where medical infrastructure is often sparse.

Engineering an Affordable Lifeline

Haemodialysis is the clinical mainstay for patients with end-stage renal disease (ESRD). It acts as an artificial kidney, filtering waste products and excess fluid from the blood. However, the recurring costs of consumables and the energy-intensive nature of water purification have long made it a “luxury” treatment in the developing world.

The IICT team, led by senior scientists specializing in membrane technology, focused on the two most significant financial bottlenecks in the dialysis process:

1. The Hollow-Fibre Haemodialyser

The “heart” of the dialysis machine is the dialyser, a plastic cylinder containing thousands of tiny, semi-permeable hollow fibres. Historically, India has relied heavily on imported filters, which cost patients between ₹700 and ₹1,000 per unit.

The IICT researchers developed a novel “spinneret” design to manufacture these fibres from polyethersulfone, a high-performance polymer. These indigenous filters are engineered to match international performance standards but can be produced for as little as ₹150 to ₹200. This reduction represents a nearly 70% drop in consumable expenses per session.

2. Advanced RO/NF Water Purification

Dialysis requires massive quantities of ultrapure water to prevent pathogens from entering a patient’s bloodstream—a complication that can lead to life-threatening sepsis. Conventional systems are often inefficient and expensive to maintain.

The scientists engineered a custom Reverse Osmosis (RO) and Nanofiltration (NF) membrane system. According to data from the pilot installations, these systems meet stringent Type-1 and Type-2 medical-grade water standards while simultaneously reducing water and electricity consumption by 25%.

Bridging the Economic Gap in Kidney Care

The implications of these cost reductions are profound. In India, a standard haemodialysis regimen requires three sessions per week. For families paying out-of-pocket, the financial strain is often the primary reason for treatment discontinuation.

“Anything that brings down consumable costs by even 30–50% can push dialysis from a luxury to a negotiable line-item in a middle- or lower-income family budget,” says Dr. Shekhar Verma, a Hyderabad-based nephrologist not involved in the IICT project.

With diabetes and hypertension—the leading drivers of CKD—on the rise, the Indian Journal of Nephrology has frequently highlighted that a large share of the population remains under-treated. By lowering the “per-session” price tag, these technologies could save individual families tens of thousands of rupees annually and allow government-funded insurance schemes to cover more patients without increasing their fiscal budgets.

From Pilot Projects to National Scale

The success in Kamareddy and Marredpally has proven that the technology is not just a laboratory concept but a viable clinical tool. These pilot deployments, managed through private dialysis service providers, reported stable performance and consistent safety metrics over several months of real-world use.

The IICT is currently in the process of technology transfer to private manufacturers. The goal is to mass-produce these components so they can be integrated into mainstream dialysis machines across the country. Experts believe this move will be particularly beneficial for smaller clinics in “Tier 2” and “Tier 3” cities, which often struggle with the capital and operational costs of imported technology.

Public Health and Policy: The “Make in India” Impact

The breakthrough aligns perfectly with the Pradhan Mantri National Dialysis Programme (PMNDP), which seeks to provide free dialysis to the poor. However, the program’s scalability has been hindered by a nearly 80% dependence on imported medical devices.

Dr. Ravi Reddy, a public-health nephrologist, noted during a recent conference that indigenous innovations are the only way to achieve universal health coverage in kidney care. “If we bundle these 70% cost savings with robust monitoring for infection control, it becomes a genuine game-changer for public health policy,” Dr. Reddy stated.

A Note of Caution: Limitations and Future Hurdles

While the headlines are promising, medical experts urge a balanced perspective on the road to widespread adoption:

• Long-term Durability: While the pilot data is encouraging, longer-term follow-up is necessary to ensure the hollow-fibre membranes do not degrade or lose efficiency after thousands of cumulative hours of use.

• Regulatory Rigor: Before these devices become the national standard, they must pass rigorous scrutiny by the Central Drugs Standard Control Organisation (CDSCO) and meet international quality benchmarks.

• Operational Overheads: A 70% reduction in consumables does not mean a 70% reduction in the entire hospital bill. Costs for specialized nursing staff, facility maintenance, and emergency care will remain constant.

• Market Competition: Some experts caution against a monopoly on indigenous tech, suggesting that multiple manufacturers should be allowed to license the IICT patents to ensure healthy competition and continued innovation.

What This Means for Patients

For the millions of Indians living with CKD, the message from Hyderabad is one of empowerment. If successfully scaled, patients can expect:

1. Lower Out-of-Pocket Costs: Reducing the likelihood of “catastrophic health expenditure” that drives families into debt.

2. Proximity to Care: More local clinics may open in rural areas because the cost of entry for dialysis infrastructure will be significantly lower.

3. Treatment Consistency: Lower costs mean fewer skipped sessions, leading to better long-term survival rates and quality of life.

As the IICT continues to refine its manufacturing processes, the focus now shifts to clinical validation and industrial production. For now, the “Hyderabad Breakthrough” stands as a testament to how local scientific research can solve the most pressing healthcare challenges of the 21st century.

Reference Section

• https://health.economictimes.indiatimes.com/news/medical-devices/iict-scientists-develop-indigenous-tech-to-reduce-dialysis-cost-20k-patients-benefit/130429851?utm_source=top_story&utm_medium=homepage

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.